CAR T-cells: current limitations and future developments - Institut Curie Accéder directement au contenu
Article Dans Une Revue Hématologie Année : 2020

CAR T-cells: current limitations and future developments

Résumé

Chimeric antigen receptor (CAR) T-cells represent a great breakthrough in the treatment of hematologic malignancies. To date, two different CAR T-cells have been approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Despite a remarkable efficacy, their use is limited by the occurrence of resistances and/or severe toxicities. A better understanding of these mechanisms and the progress in molecular intervention are paving the way for the development of new generations of CAR T-cells, with enhanced efficacy and/or reduced toxicity. Here, we review the mechanisms of resistance and toxicity, and the strategies which are envisioned to optimize CAR T-cell therapy.
Fichier non déposé

Dates et versions

hal-03169538 , version 1 (15-03-2021)

Identifiants

Citer

Marion Alcantara, Roch Houot. CAR T-cells: current limitations and future developments. Hématologie, 2020, 26 (S5), pp.38-45. ⟨10.1684/hma.2020.1583⟩. ⟨hal-03169538⟩
55 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More